KCM
Kynam Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $75.8M | Sell |
8,463,742
-464,781
| -5% | -$4.16M | 8.16% | 5 |
|
|
2025
Q1 | $67M | Sell |
8,928,523
-156,845
| -2% | -$1.18M | 5.63% | 5 |
|
|
2024
Q4 | $68.3M | Hold |
9,085,368
| – | – | 4.04% | 8 |
|
|
2024
Q3 | $69M | Buy |
9,085,368
+258,658
| +3% | +$1.97M | 5.29% | 8 |
|
|
2024
Q2 | $54.5M | Buy |
8,826,710
+2,299,219
| +35% | +$14.2M | 4.21% | 8 |
|
|
2024
Q1 | $33.2M | Buy |
6,527,491
+1,927,491
| +42% | +$9.79M | 3.47% | 9 |
|
|
2023
Q4 | $27.6M | Buy |
4,600,000
+1,466,807
| +47% | +$8.79M | 3.05% | 11 |
|
|
2023
Q3 | $22.2M | Buy |
3,133,193
+284,996
| +10% | +$2.02M | 3.63% | 9 |
|
|
2023
Q2 | $20.1M | Buy |
2,848,197
+1,848,197
| +185% | +$13M | 2.76% | 9 |
|
|
2023
Q1 | $8.34M | Buy |
+1,000,000
| New | +$8.34M | 1.08% | 19 |
|
|
2022
Q4 | – | Sell |
-435,117
| Closed | -$5.48M | – | 33 |
|
|
2022
Q3 | $5.48M | Sell |
435,117
-501,446
| -54% | -$6.32M | 1.16% | 19 |
|
|
2022
Q2 | $9.91M | Buy |
+936,563
| New | +$9.91M | 2.53% | 11 |
|